A study found that mepolizumab improved exacerbation-related outcomes in patients with COPD and type 2 inflammation, characterized by both consistently and intermittently elevated blood eosinophil count. Persistent BEC elevation is not required to identify treatable eosinophilic phenotypes in COPD.
Lung Sask in collaboration with RESPTREC® offers the Professional Education Portal as a method for respiratory educators and health care providers to enhance their professional learning with continuing education opportunities.
Over 6000+ more articles available in the Professional Education Portal.
Read articles and watch video presentations on the most recent research, position papers and guidelines. Track your CE time with the provided logbook.